<DOC>
	<DOCNO>NCT01592786</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability memantine pediatric ( 6-12 year old ) patient autism , Asperger 's Disorder , Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS ) identify responder participation follow-up randomize withdrawal study .</brief_summary>
	<brief_title>An Open-Label Safety Study Memantine Pediatric Patients With Autism , Asperger 's Disorder , Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS )</brief_title>
	<detailed_description>This 50-week multicenter multinational clinical study comprise 2-week screening period , 6-week open-label dose-titration period follow variable duration maintenance period ( 42 week ) . Patients least 12 week investigational product exposure meet protocol specify responder criterion two consecutive visit separate least two week eligible transition randomize withdrawal study . A responder define patient demonstrates least 10 point improvement ( reduction score ) Social Responsiveness Scale ( SRS ) total raw score relative Visit 1 total raw score . Weight base dose limit select study ensure exposure term area curve ( AUC ) less predefined limit 2100 ng·h/mL represent 10-fold low exposure observe No observed adverse effect level ( NOAEL ) 15 mg/kg/day juvenile rat . The weight-based dose limit study follow : - Group A : ≥ 60 kg ; maximum 15 mg/day - Group B : 40-59 kg ; maximum 9 mg/day - Group C : 20-39 kg ; maximum 6 mg/day - Group D : &lt; 20 kg ; maximum 3 mg/day</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Male female outpatient . 2 . Age 612 . 3 . Meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) diagnostic criterion autism , Asperger 's Disorder , Pervasive Developmental Disorder Not Otherwise Specified ( PDDNOS ) 4 . Have family sufficiently organize stable guarantee adequate safety monitor continuous attendance clinic visit duration study 1 . Have enrol Study MEMMD57A 2 . Medical condition might interfere conduct study , confound interpretation study result , endanger patient 's wellbeing . 3 . Participation clinical investigation use experimental drug within 30 day screen . 4 . Having primary psychiatric ( Axis I ) diagnosis autism , Asperger 's Disorder , PDDNOS . 5 . Meeting DSMIVTR criterion bipolar I disorder , psychotic disorder otherwise specify , posttraumatic stress disorder , schizophrenia , major depressive disorder within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Autism Spectrum Disorder ( ASD )</keyword>
	<keyword>Autism</keyword>
	<keyword>Autistic Disorder</keyword>
	<keyword>Asperger 's Disorder</keyword>
	<keyword>Asperger 's</keyword>
	<keyword>Pervasive Developmental Disorder Not Otherwise Specified ( PDD-NOS )</keyword>
	<keyword>Memantine</keyword>
	<keyword>Pediatric Disorder</keyword>
</DOC>